Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-01-04

Clinical Trial Update: Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Xyntha in children under 6 with Hemophilia A was terminated; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xyntha (recombinant coagulation factor VIII)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 3 | Status: TERMINATED | Results posted: 2011-01-04